By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion said today that its revenues rose to $431,000 in the first quarter, compared to $73,000 in Q1 2010, as more than 3,000 of its OVA1 ovarian cancer tests were performed.

The firm's results fell short of analysts' expectations of $520,000 in revenues.

For the three months ended March 31, product revenues came in at $317,000, compared to none a year ago, and licensing revenues were $114,000, up from $73,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.